Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
XB

WKN: A3EFQB | ISIN: US9840156023 | Ticker: 3XB0
NASDAQ
19.11.26 | 20:12
1,510 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
XENETIC BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
XENETIC BIOSCIENCES INC 5-Tage-Chart

Aktuelle News zur XENETIC BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
13.11.Xenetic Biosciences GAAP EPS of -$0.72, revenue of $0.7M2
13.11.Xenetic Biosciences, Inc.: Xenetic Biosciences Reports Third Quarter 2026 Financial Results and Highlights Strategic Business Updates547Proposed share exchange transaction expected to create a multi-indication clinical stage company focused on targeting neutrophil extracellular traps (NETs)Joint pipeline includes four first-in-class...
► Artikel lesen
13.11.Xenetic Biosciences, Inc. - 8-K, Current Report3
12.11.Xenetic Biosciences, Inc. - 10-Q, Quarterly Report-
04.11.Xenetic Biosciences, Inc.: Xenetic Biosciences Announces Oral Presentation at 68th ASH Annual Meeting Highlighting DNase I as a Potential Strategy to Overcome CAR T-Cell Resistance374Research examines a self-reinforcing resistance niche created by extracellular chromatin released during CAR T-cell killing and its reversal by DNase IPresentation selected for ASH scientific session...
► Artikel lesen
XENETIC BIOSCIENCES Aktie jetzt für 0€ handeln
15.10.Xenetic partner doses first patient in DNase CAR T-cell study3
15.10.Xenetic Biosciences, Inc.: Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma420First clinical evaluation of Xenetic's systemic DNase technology as an adjunct to CAR T-cell therapy in an investigator-initiated study conducted at Tel Aviv Sourasky University Medical CenterInitial...
► Artikel lesen
23.09.Xenetic Biosciences, Inc. - 8-K, Current Report1
16.09.Xenetic Biosciences und Santersus AG geben endgültige Vereinbarung über einen Aktientausch bekannt, um einen weltweit führenden Anbieter von auf NETs ausgerichteten Therapeutika zu schaffen505Durch die Transaktion soll ein an der Nasdaq notiertes im klinischen Stadium für mehrere Indikationen befindliches Unternehmen entstehen, das sich auf die gezielte Bekämpfung von neutrophilen...
► Artikel lesen
16.09.Xenetic Biosciences übernimmt Santersus im Rahmen einer reinen Aktientransaktion2
16.09.Xenetic Biosciences to acquire Santersus in all-stock deal3
16.09.Xenetic Biosciences, Inc.: Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics433Transaction expected to create a Nasdaq-listed, multi-indication clinical-stage company focused on targeting neutrophil extracellular traps (NETs), a driver of disease across critical care, autoimmune...
► Artikel lesen
16.09.Xenetic Biosciences, Inc. - 8-K, Current Report2
07.08.Xenetic Biosciences reports Q2 results4
07.08.Xenetic Biosciences, Inc.: Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform1.074Expanded collaborative research initiatives reinforce the Company's long-term DNase development strategyOngoing generation of translational data designed to support future clinical development and deepen...
► Artikel lesen
07.08.Xenetic Biosciences, Inc. - 8-K, Current Report4
06.08.Xenetic Biosciences, Inc. - 10-Q, Quarterly Report1
04.06.Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma471Company evaluating systemic recombinant human DNase I in combination with anti-CD19 CAR T cells targeting lymphoma patients in stable or progressive disease at lymphodepletion Company reported strong...
► Artikel lesen
01.06.Xenetic: DNase I steigert Wirksamkeit von CAR-T-Therapie in präklinischen Studien3
01.06.Xenetic Biosciences, Inc.: Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival416New preclinical and translational findings position DNase I as a potentially transformative adjunct therapy for CAR-T treatment in aggressive B cell malignanciesData highlight potential of DNase I to...
► Artikel lesen
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1